Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medication safety

EMA to review safety of direct-acting antivirals after reports of hepatitis B reactivation

The European Medicines Agency (EMA) is to review the safety of direct-acting antivirals used to treat patients with chronic hepatitis C infection.

The decision follows reports of cases of hepatitis B being reactivated in patients infected with both the hepatitis B and C viruses who were being treated with the antivirals. The patients had been prescribed the antivirals to treat their hepatitis C.

The products at the centre of the review are: daclatasvir (Daklinza); dasabuvir (Exviera); sofosbuvir/ledipasvir (Harvoni); simeprevir (Olysio); sofosbuvir (Sovaldi); and ombitasvir/paritaprevir/ritonavir (Viekirax). They can be used by patients without the need for treatment with interferons, which are generally less well tolerated.

The direct-acting antivirals work by blocking the action of proteins in the hepatitis C virus that are essential for it to replicate.

The review, which was announced after the latest EMA Pharmacovigilance Risk Assessment Committee (PRAC) meeting on 14–17 March 2016, will be carried out by PRAC and follows a request by the European Commission (EC). The recommendations will then be forwarded to the EMA’s Committee for Medicinal Products for Human Use but will need final approval by the EC.

Patients are advised to speak to their pharmacist or doctor if they have any concerns about the antivirals pending the outcome of the review, the EMA says.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200903

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • European Medicines Agency headquarters

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.